The DOI matches its Crossref record; 79 of the 81 references it cites were found in a registry or an index; 19 of the 88 sources its claims cite were checked for support.
The Ocular Gene Delivery Landscape
Open accessAbstract
The eye is at the forefront of developing therapies for genetic diseases. With the FDA approval of the first gene-therapy drug for a form of congenital blindness, numerous studies have been initiated to develop gene therapies for other forms of eye diseases. These examinations have revealed new information about the benefits as well as restrictions to using drug-delivery routes to the different parts of the eye. In this article, we will discuss a brief history of gene therapy and its importance to the eye and ocular delivery landscape that is currently being investigated, and provide insights into their advantages and disadvantages. Efficient delivery routes and vehicle are crucial for an effective, safe, and longer-lasting therapy.
Overview
CoChat Summary
TL;DR
This review surveys ocular gene delivery, comparing intravitreal, subretinal, and suprachoroidal routes and non-viral versus viral vectors for retinal gene therapy. It concludes that rAAVs are currently the safest and most reliable vehicles, while non-viral systems offer payload and immunogenicity advantages but remain untested in ocular clinical trials.
Key findings
- The retina can be accessed via three routes—intravitreal, subretinal, and suprachoroidal—with choice depending on target cell type. Subretinal injection is invasive and carries risks of retinal tears, detachments, and macular holes; intravitreal injection is safer but poorly transduces the outer retina due to the inner limiting membrane and vitreous; suprachoroidal injection is less invasive but requires specialized needles and AAV vectors struggle to traverse the choroid to reach RPE and photoreceptors.
- Over 300 genes are associated with inherited retinal degenerations (IRDs), and >3 million people in the United States have vision impairment, expected to double to ~6 million by 2050.
- Non-viral vectors include lipid-, peptide-, polymer-based nanoparticles and naked DNA. They can accommodate large plasmid DNA, are less immunogenic, carry no insertional mutagenesis risk, and have low production cost; ECO nanoparticles delivered RPE65 in Rpe65−/− mice, and CK30-PEG-compacted nanoparticles transfected RPE and photoreceptors and treated Rpe65−/− and Abca4−/− mice. However, non-viral ocular gene delivery has not yet entered clinical trials for ocular diseases.
- Viral vectors differ in packaging capacity: retrovirus 8 kb, lentivirus 8–9 kb, adenovirus 30–40 kb (about 18.5% of clinical trials use adenoviral vectors), and AAV genome 4.7 kb with therapeutic payload under 5 kb. rAAV capsid engineering—AAV8, AAV8(Y733F), AAV7m8, AAV8BP2, and AAV-PHP.eB—improves retinal tropism; Luxturna was FDA-approved in 2018. rAAV limitations include immune responses, neutralizing antibodies, and <5 kb packaging capacity.
Methods
- Narrative review; no primary experimental design, sample, or statistical analysis is reported. It synthesizes literature on gene therapy history, retinal disease genetics, ocular delivery routes, and vector classes.
- Discusses non-viral vectors (lipid-based, peptide-based, polymer-based, naked DNA) and viral vectors (retroviral, lentiviral, adenoviral, AAV), citing animal-model and clinical-trial examples.
- No systematic search strategy, inclusion criteria, or meta-analysis is described.
Limitations
- The paper does not state limitations of its own review. Evident from the text: it is a narrative review without systematic search criteria, quantitative synthesis, or formal risk-of-bias assessment.
- Field limitations stated in the paper include anatomical barriers in the retina and pH sensitivity of nanoparticles that hinder efficient non-viral delivery and prolonged gene expression; species-specific differences mean promising rodent results may not hold in larger species such as sheep, pigs, and non-human primates.
- rAAV limitations stated include intraocular inflammation, loss of efficacy, neutralizing antibodies against capsids, and limited transgene size (<5 kb), with dual AAV vector systems and nanoparticles being developed as alternatives.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
11 Valid · 3 Not valid · 53 Not checked · 16 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The NPs that undergo clathrin-mediated endocytosis can end up in endosomes, which mature to endolysosomes and undergo degradation.”
§ The Ocular Gene Delivery Landscape > 2. Gene Therapy > 2.3. Vectors for Gene Delivery
What the sources say
- Supportedcites [30] Behzadi, 2017, Cellular uptake of nanoparticles: Journey inside the cell, Chem. Soc. Rev. source
Section 3.2 says particles entering through clathrin-mediated endocytosis frequently end up in degradative lysosomes. Section 6 describes endocytic cargo entering early endosomes, which can mature into late endosomes and fuse with lysosomes to form endolysosomes, where the contents encounter degradation enzymes. The claim’s “can” reflects that this is one possible fate. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Several liposome formulations have been tested for DNA delivery to ocular tissues using intravitreal and subretinal routes [33].”
§ The Ocular Gene Delivery Landscape > 2. Gene Therapy > 2.3. Vectors for Gene Delivery
What the sources say
- Could not verifycites [33] Balazs, 2011, Liposomes for use in gene delivery, J. Drug Deliv. sourceExperimental — accuracy not yet measured
Our copy of Balazs & Godbey (2011) is a complete review organised by lipid charge (Sections 3 'Cationic Lipids', 4 'Neutral Lipids', 6 'Concluding Remarks') and discusses DOTMA/DOTAP/DC-Chol/DOSPA/DOGS formulations, DOPE helper lipids and packing phases, with in vivo/organ examples limited to mouse lung, hepatoma (Hep G2) cells, airways, peritoneal tumour and developing embryos (Sec. 3.1.1, Sec. 4.1, refs 29-30, 60-63). No passage in our copy mentions ocular or eye tissue, the retina, or intravitreal or subretinal administration (searched: intravitreal, subretinal, eye, retina, ocular administration route), so the specific point the citing sentence attributes to this source is not addressed here. Absence is not contradiction, and the paper names no alternative origin for the ocular claim. (LLM, conf=0.70)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“Liposomes-protamine-DNA (LPD), in combination with a nuclear localization signal (NLS) peptide and a transactivator of transcription (TAT) peptide, make cell-specific and efficient gene delivery with sustained gene expression [35].”
§ The Ocular Gene Delivery Landscape > 2. Gene Therapy > 2.3. Vectors for Gene Delivery
What the sources say
- Supportedcites [35] Wang, 2015, Lipid Nanoparticles for Ocular Gene Delivery, J. Funct. Biomater. source
Section 4, “Lipid-Based Nanoparticles,” directly describes an LPD nanoparticle combined with NLS and TAT peptides for efficient, cell-specific gene delivery to eye tissues with sustained expression. Section 9 clarifies that cell specificity is achieved through cell-specific promoters, rather than the peptides alone. (LLM, conf=0.95)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Since then, AAV-mediated gene delivery into the retina has been used in several proof-of-concept studies to target photoreceptors or the RPE in mice and larger models (such as dogs) [63,64,65].”
§ The Ocular Gene Delivery Landscape > 2. Gene Therapy > 2.3. Vectors for Gene Delivery
What the sources say
- Supportedcites [63] Buck, T.M., and Wijnholds, J. (2020). Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays. Int. J. Mol. Sci., 21. source
Section 5.6.2 reports rAAV delivery to photoreceptors and RPE cells in mouse retinal-disease models. The References also list AAV-mediated cone rescue in a mouse model and gene therapy rescuing photoreceptor blindness in dogs. Together, these support the broad statement that retinal AAV delivery has been used in proof-of-concept animal studies. (LLM, conf=0.86)
- Not checked yetcites [64] Acland, 2001, Gene therapy restores vision in a canine model of childhood blindness, Nature Genet. source
- Supportedcites [65] Beltran, 2012, Gene therapy rescues photoreceptor blindness in dogs and paves the way for treating human X-linked retinitis pigmentosa, Proc. Natl. Acad. Sci. USA source
This paper supports the dog-photoreceptor example among the sentence’s several citations. The Materials and Methods describe subretinal AAV2/5 gene delivery in dogs, and the Results report expression in photoreceptors and photoreceptor preservation in treated areas; this citation need not independently establish the mouse or RPE examples. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Mutations of these residues prevent the phosphorylation and subsequent ubiquitination and degradation [70].”
§ The Ocular Gene Delivery Landscape > 2. Gene Therapy > 2.3. Vectors for Gene Delivery
What the sources say
- Partly supportedcites [70] Hickey, 2017, Tropism of engineered and evolved recombinant AAV serotypes in the rd1 mouse and ex vivo primate retina, Gene Ther. sourceExperimental — accuracy not yet measured
The Introduction of Hickey et al. (2017) states that 'Mutation of surface tyrosine (Y) residues to phenylalanine (F) was found to reduce the rate of proteasome-mediated degradation and to significantly increase transgene expression in vitro and in vivo', supporting the degradation half of the claim. However, our copy nowhere mentions phosphorylation of those tyrosines or their subsequent ubiquitination, so the mechanistic chain the citing sentence attributes to this source is not in it. The paper also presents the degradation finding as someone else's result, hedged ('was found to') and credited to its reference 9 (Zhong et al., PNAS 2008), rather than as an original observation. (LLM, conf=0.75)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
36 more claims · 4 with their cited sources checked
Create a free account to see all 83 claims and to verify the 69 references still open.
- It may state two separate claims as one. 23
- Probably not a substantial claim. 23
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, lipid-based transfection systems have shown success in their ability to transfer the target genes into retinal cells in several studies, and multiple lipid-based drugs for eye diseases are already available in the clinic35,79,87–91 and for the delivery of CRISPR or ribonucleoproteins for base editing.92,93”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [91]
Experimental — accuracy not yet measuredIn the citing paper
“The suprachoroidal injection is a recent breakthrough in the retinal gene-delivery landscape and may provide a unique opportunity to perform less invasive surgeries31,32.”
From An adeno-associated virus variant enabling efficient ocular-directed gene delivery across species (2024) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ The Ocular Gene Delivery Landscape > 3. Conclusions
“the non-viral gene delivery strategy has not yet been used in any clinical trials for ocular diseases.”
§ The Ocular Gene Delivery Landscape > 2. Gene Therapy > 2.3. Vectors for Gene Delivery
“Clinical trials have been initiated for non-infectious uveitis (NIU) disease of the eye using naked DNA delivery.”
Citations
Cites
Cellular uptake of nanoparticles: Journey inside the cell
Behzadi, S., Serpooshan, V., Tao, W., Hamaly, M. A., Alkawareek, M. Y., Dreaden, E. C., Brown, D., Alkilany, A. M., Farokhzad, O. C., & Mahmoudi, M. (2017) · Chemical Society Reviews · doi:10.1039/c6cs00636a · Cited by 2,859 · cited 1×
“However, caveolinmediated endocytosis encapsulates the NPs in caveolae vesicles that enter early endosomes or endoplasmic reticulum and escape degradation [30].”
BackgroundAdeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Russell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31868-8 · Cited by 1,952 · cited 1×
“Notably, one of the studies involving the delivery of the RPE65 gene into mutant dogs showed therapeutic potential, which subsequently led to the approval of the first gene therapy drug (LuxturnaTM) by the Food and Drug Administration in 2018 [66].”
BackgroundT Lymphocyte-Directed Gene Therapy for ADA − SCID: Initial Trial Results After 4 Years
Blaese, R. M., Culver, K. W., Miller, A. D., Carter, C. S., Fleisher, T., Clerici, M., Shearer, G., Chang, L., Chiang, Y., Tolstoshev, P., et al. (1995) · Science · doi:10.1126/science.270.5235.475 · Cited by 1,550 · cited 1×
“French Anderson and colleagues introduced the wild-type adenosine deaminase (ADA) gene into the patient [6].”
BackgroundHildebrandt, F., Benzing, T., & Katsanis, N. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1010172 · Cited by 1,331
Gene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202
The renewal of photoreceptor cell outer segments
Young, R. W. (1967) · The Journal of Cell Biology · doi:10.1083/jcb.33.1.61 · Cited by 1,184 · cited 1×
“Photoreceptors, on the other hand, are predominantly endocytic [28,29].”
BackgroundEngineering adeno-associated virus vectors for gene therapy
Li, C., & Samulski, R. J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0205-4 · Cited by 1,175 · cited 2×
“Some of the drugs that use retroviral gene delivery include strimvelis for SCID and Yescarta for large B cell lymphoma [48].”
BackgroundGene therapy clinical trials worldwide to 2012 – an update
Ginn, S. L., Alexander, I. E., Edelstein, M. L., Abedi, M. R., & Wixon, J. (2013) · The Journal of Gene Medicine · doi:10.1002/jgm.2698 · Cited by 1,159
Effect of genome size on AAV vector packaging
Wu, Z., Yang, H., & Colosi, P. (2010) · Molecular Therapy · doi:10.1038/mt.2009.255 · Cited by 1,029 · cited 2×
“Neutralizing antibodies against the capsid can also reduce the therapeutic potential of the gene delivery [76].”
Background
Research works printed but not linked: 2
- Kandel, E.R. (2013). Principles of Neural Science, McGraw-Hill. [5th ed.].
- Audo, 2015, Early findings in a phase I/IIa clinical program for stargardt disease (STGD1, MIM # 248200), Invest. Ophthalmol. Vis. Sci., 56, 3819
Cited by
Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions
Drag, S., Dotiwala, F., & Upadhyay, A. K. (2023) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.64.7.39 · Cited by 145
Overview of Recent Advances in Nano-Based Ocular Drug Delivery
Liu, L.-C., Chen, Y., & Lu, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015352 · Cited by 172
“In such scenarios, light activation serves as a means to initiate the release of drugs within these cells and facilitate delivery into the cytoplasm [182].”
BackgroundNano-based eye drop: Topical and noninvasive therapy for ocular diseases
Wang, C., & Pang, Y. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114721 · Cited by 114
An adeno-associated virus variant enabling efficient ocular-directed gene delivery across species
Luo, S., Jiang, H., Li, Q., Qin, Y., Yang, S., Li, J., Xu, L., Gou, Y., Zhang, Y., Liu, F., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48221-4 · Cited by 39
Supe, S., Upadhya, A., Tripathi, S. D., Dighe, V. D., & Singh, K. (2023) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01281-9 · Cited by 32
Metadata
- Authors
- Sahu, B., Chug, I., & Khanna, H.
- Affiliations
- University of Massachusetts Chan Medical School (US)
- Corresponding author
- Khanna, Hemant
- ORCID
- Khanna, Hemant
- Venue
- Biomolecules
- Publisher
- MDPI AG
- Published
- 2021-08-01
- Volume
- 11
- Issue
- 8
- Pages
- 1135
- ISSN
- 2218-273X (ISSN-L)
- PMC
- PMC8394578
- OpenAlex
- W3191982495
- Cited by
- 28
- References
- 81
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 9 · 2023: 7 · 2022: 2 · 2021: 2
- FWCI
- 0.46
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Biomolecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- The Journal of the American Medical Association (JAMA) Network (American Medical Association) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Eye Institute (EY022372)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Keywords
- ocular gene therapy, ocular drug delivery, eye diseases, congenital blindness, history of gene therapy
- MeSH terms
- Choroidal Effusions, Animals, DNA, Eye, Eye Diseases, Genetic Vectors, Humans, Liposomes, Peptides, Viruses, Vitreous Body, Genetic Therapy, Gene Transfer Techniques, Nanoparticles, Intravitreal Injections, Subretinal Fluid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Ocular Gene Delivery Landscape. https://app.cochat.ai/papers/10.3390/biom11081135
- The paper
- Sahu, B., Chug, I., & Khanna, H. (2021). The Ocular Gene Delivery Landscape. Biomolecules. https://doi.org/10.3390/biom11081135
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

